SCHEMBL22672437

SCHEMBL22672437

CC(C)c1ccc2c(C(=O)O)coc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 3/20 0.48
▸ IKBKE Q14164 2/20 0.48
▸ GPR35 Q9HC97 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ABCC4 O15439 1/20 0.42
▸ TTR P02766 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ ADRA1A P35348 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ EIF4A3 P38919 2/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ MAOB P27338 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ CSNK2B P67870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530849 0.78 SMN1; SMN2 (0.59) KDM4ENPC1PKMRAB9AMAOB
SCHEMBL29933509 0.78 SMN1; SMN2 (0.59) KDM4ENPC1PKMRAB9AMAOB
SCHEMBL204082 0.76 PIM1 (0.54) KDM4ENPC1TTRGAAPKM
SCHEMBL20409266 0.76 TRPA1 (0.46) TBK1IKBKEKDM4ENPC1GAA
SCHEMBL23320560 0.75 KDM4E (0.50) GPR35KDM4ENPC1PKMRAB9A
SCHEMBL31704456 0.75 KDM4E (0.50) GPR35KDM4ENPC1PKMRAB9A
SCHEMBL23359886 0.75 KEAP1 (0.46) KDM4ENPC1TTRGAARAB9A
SCHEMBL12433977 0.74 CA12 (0.64) KDM4ENPC1RAB9AMAOBMAPT
SCHEMBL10216166 0.74 PTPN1 (0.44) TBK1KDM4EGAAPTPN1MAPT
SCHEMBL17615540 0.74 PTPN1 (0.47) TBK1IKBKEGAAPTPN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-04-20 — — US disclosed
US-20200361920-A1 ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2020-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF PPID, PPIF, PPIL1 TBK1 4169/4885IKBKE 1561/4885GPR35 1734/4885
US-20200361920-A1 ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF SLC10A1, NR1H4, SLC10A2 TBK1 2515/4885IKBKE 1089/4885GPR35 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback